Seroprevalence of Measles, Mumps, Rubella, and Varicella-Zoster Virus and Seroresponse to the Vaccinations in Adult Solid Organ Transplant Candidates.
Humans
Adult
Infant
Herpesvirus 3, Human
Mumps
/ diagnosis
Seroepidemiologic Studies
Retrospective Studies
Vaccines, Combined
/ adverse effects
Measles
/ epidemiology
Rubella
/ epidemiology
Chickenpox Vaccine
Chickenpox
/ prevention & control
Vaccination
Organ Transplantation
/ adverse effects
Antibodies, Viral
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
medline:
27
9
2023
pubmed:
13
6
2023
entrez:
13
6
2023
Statut:
ppublish
Résumé
Updating live vaccines such as measles, mumps, rubella, and varicella (MMRV) is an important step in preparing patients for solid organ transplant (SOT) to prevent morbidity from these preventable diseases. However, data for this approach are scarce. Thus, we aimed to describe the seroprevalence of MMRV and the efficacy of the vaccines in our transplant center. Pre-SOT candidates >18 y of age were retrospectively retrieved from SOT database in Memorial Hermann Hospital Texas Medical Center. MMRV serologies are routinely screened at the time of pretransplant evaluation. We divided patients into 2 groups: MMRV-positive group versus MMRV-negative group, patients with positive all MMRV serologies and with negative immunity to at least 1 dose of MMRV, respectively. A total of 1213 patients were identified. Three hundred ninety-four patients (32.4%) did not have immunity to at least 1 dose of MMRV. Multivariate analysis was conducted. Older age (odds ratio [OR]: 1.04) and liver transplant candidates (OR: 1.71) were associated with seropositivity. Previous history of SOT (OR: 0.54) and pancreas/kidney transplant candidates (OR: 0.24) were associated with seronegativity. Among 394 MMRV seronegative patients, 60 patients received 1 dose of MMR vaccine and 14 patients received 1 dose of varicella-zoster virus vaccine without severe adverse events. A total of 35% (13/37) of patients who had follow-up serologies did not have a serological response. A significant number of pre-SOT candidates were not immune to at least 1 dose of MMRV. This highlights the importance of MMRV screening and vaccinations pre-SOT. Postvaccination serological confirmation should be performed to evaluate the necessity for a second dose.
Sections du résumé
BACKGROUND
Updating live vaccines such as measles, mumps, rubella, and varicella (MMRV) is an important step in preparing patients for solid organ transplant (SOT) to prevent morbidity from these preventable diseases. However, data for this approach are scarce. Thus, we aimed to describe the seroprevalence of MMRV and the efficacy of the vaccines in our transplant center.
METHODS
Pre-SOT candidates >18 y of age were retrospectively retrieved from SOT database in Memorial Hermann Hospital Texas Medical Center. MMRV serologies are routinely screened at the time of pretransplant evaluation. We divided patients into 2 groups: MMRV-positive group versus MMRV-negative group, patients with positive all MMRV serologies and with negative immunity to at least 1 dose of MMRV, respectively.
RESULTS
A total of 1213 patients were identified. Three hundred ninety-four patients (32.4%) did not have immunity to at least 1 dose of MMRV. Multivariate analysis was conducted. Older age (odds ratio [OR]: 1.04) and liver transplant candidates (OR: 1.71) were associated with seropositivity. Previous history of SOT (OR: 0.54) and pancreas/kidney transplant candidates (OR: 0.24) were associated with seronegativity. Among 394 MMRV seronegative patients, 60 patients received 1 dose of MMR vaccine and 14 patients received 1 dose of varicella-zoster virus vaccine without severe adverse events. A total of 35% (13/37) of patients who had follow-up serologies did not have a serological response.
CONCLUSIONS
A significant number of pre-SOT candidates were not immune to at least 1 dose of MMRV. This highlights the importance of MMRV screening and vaccinations pre-SOT. Postvaccination serological confirmation should be performed to evaluate the necessity for a second dose.
Identifiants
pubmed: 37309028
doi: 10.1097/TP.0000000000004681
pii: 00007890-202310000-00029
doi:
Substances chimiques
Vaccines, Combined
0
Chickenpox Vaccine
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2279-2284Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Chong PP, Avery RK. A comprehensive review of immunization practices in solid organ transplant and hematopoietic stem cell transplant recipients. Clin Ther. 2017;39:1581–1598.
Centers for Disease Control and Prevention. Measles cases and outbreaks . Published February 28, 2023. Available at https://www.cdc.gov/measles/cases-outbreaks.html . Accessed March 12, 2023.
Marlow M, Leung J, Marin M, et al. Mumps - vaccine preventable diseases surveillance manual. Centers for Disease Control and Prevention. Published December 16, 2022. Available at https://www.cdc.gov/vaccines/pubs/surv-manual/chpt09-mumps.html . Accessed March 12, 2023.
Akiyode O, Rungkitwattanakul D, Emezienna N, et al. The resurgence of mumps. U.S. Pharmacist. Published May 17, 2019. Available at https://www.uspharmacist.com/article/the-resurgence-of-mumps . Accessed March 12, 2023.
Harris County Public Health. Measles health advisory . Available at https://mailchi.mp/83c540626fd1/measles-health-advisory?e=57de29abea . Accessed March 12, 2023.
Centers for Disease Control and Prevention. Varicella outbreak identification, investigation, and control . Published November 30, 2021. Available at https://www.cdc.gov/chickenpox/outbreaks.html . Accessed March 12, 2023.
Lopez AS, Zhang J, Marin M. Epidemiology of varicella during the 2-dose varicella vaccination program—United States, 2005-2014. MMWR Morb Mortal Wkly Rep. 2016;65:902–905.
Sternfeld T, Spöri-Byrtus V, Riediger C, et al. Acute measles infection triggering an episode of liver transplant rejection. Int J Infect Dis. 2010;14:e528–e530.
Baas MC, Van Donselaar KAMI, Florquin S, et al. Mumps: not an innocent bystander in solid organ transplantation. Am J Transplant. 2009;9:2186–2189.
Mazariegos GV, Green M, Reyes J, et al. Rubella infection after orthotopic liver transplantation. Pediatr Infect Dis J. 1994;13:161–162.
Rezahosseini O, Sørensen SS, Perch M, et al. Measles, mumps, rubella, and varicella zoster virus serology and infections in solid organ transplant recipients during the first year posttransplantation. Clin Infect Dis. 2021;73:e3733–e3739.
Kreiger-Benson E, Gelb B, Neumann HJ, et al. Measles outbreak risk assessment for transplant candidates and recipients. Am J Transplant. 2021;21:338–343.
Kotton C, Huprikar S. Guidance on increased measles activity and solid organ transplantation. American Society of Transplantation. Published February 23, 2015. Available at https://www.myast.org/news/guidance-increased-measles-activity-and-solid-organ-transplantation . Accessed March 12, 2023.
Gourishankar S, McDermid JC, Jhangri GS, et al. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant. 2004;4:108–115.
Acar S, Gencdal G, Kirimlioglu H, et al. Varicella-zoster virus-induced hepatitis in a liver transplant recipient: a case report. Transplant Proc. 2019;51:1193–1195.
Wang D, Wang JQ, Tao XG. Fatal visceral disseminated varicella-zoster virus infection in a renal transplant recipient: a case report. World J Clin Cases. 2021;9:9168–9173.
Danziger-Isakov L, Kumar D; AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: guidelines from the American Society of Transplantation infectious diseases community of practice. Clin Transplant. 2019;33:e13563.
Seckin ZI, Libertin CR, Brumble LM. Serologic screening and infectious diseases consultation in renal transplant candidates for measles, mumps, rubella and varicella. Rom J Intern Med. 2021;59:159–165.
Centers for Disease Control and Prevention. Adult immunization schedule by vaccine and age group . Published February 18, 2022. Available at https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html . Accessed May 27, 2022.
McQuillan GM, Kruszon-Moran D, Hyde TB, et al. Seroprevalence of measles antibody in the US population, 1999–2004. J Infect Dis. 2007;196:1459–1464.
Lebo EJ, Kruszon-Moran DM, Marin M, et al. Seroprevalence of measles, mumps, rubella and varicella antibodies in the United States population, 2009–2010. Open Forum Infect Dis. 2015;2:ofv006.
Marquis SR, Logue JK, Chu HY, et al. Seroprevalence of measles and mumps antibodies among individuals with cancer. JAMA Netw Open. 2021;4:e2118508.
Hostetler HP, Neely ML, Lydon E, et al. Immunity to varicella, measles, and mumps in patients evaluated for lung transplantation. Am J Transplant. 2021;21:2864–2870.
Gastanaduy P, Haber P, Rota P, et al. The Pink Book, chapter 13: Measles. Centers for Disease Control and Prevention. Published September 21, 2022. Accessed March 12, 2023. https://www.cdc.gov/vaccines/pubs/pinkbook/meas.html
Sørup S, Englund H, Laake I, et al. Revaccination with measles-mumps-rubella vaccine and hospitalization for infection in Denmark and Sweden—an interrupted time-series analysis. Vaccine. 2022;40:1583–1593.
World Health Organization. Manual for the laboratory-based surveillance of measles, rubella, and congenital rubella syndrome . Available at https://www.who.int/publications/m/item/chapter-9-manual-for-the-laboratory-based-surveillance-of-measles-rubella-and-congenital-rubella-syndrome . Accessed March 12, 2023.
Kontio M, Jokinen S, Paunio M, et al. Waning antibody levels and avidity: implications for MMR vaccine-induced protection. J Infect Dis. 2012;206:1542–1548.
Anichini G, Gandolfo C, Fabrizi S, et al. Seroprevalence to measles virus after vaccination or natural infection in an adult population, in Italy. Vaccines (Basel). 2020;8:66.
Murphy J, Vallières F, Bentall RP, et al. Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. Nat Commun. 2021;12:29.
Gardiner A, Liu K, Bonnichsen M, et al. Immunity to vaccine-preventable viral infections in Australians being evaluated for liver transplantation. Transplantation. 2019;103:2318–2322.
Centers for Disease Control and Prevention. Measles, mumps, and rubella (MMR) vaccination. Published November 18, 2022. Available at https://www.cdc.gov/vaccines/vpd/mmr/public/index.html . Accessed March 12, 2023.
Costales C, Sahoo MK, Huang C, et al. Vaccine-associated measles encephalitis in immunocompromised child, California, USA. Emerg Infect Dis. 2022;28:906–908.
Rubin LG, Levin MJ, Ljungman P, et al.; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:e44–100.
L’Huillier AG, Hirzel C, Ferreira VH, et al. Evaluation of recombinant herpes zoster vaccine for primary immunization of varicella-seronegative transplant recipients. Transplantation. 2021;105:2316–2323.